Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
Type:
Grant
Filed:
June 7, 2022
Date of Patent:
April 30, 2024
Assignee:
Clarity Pharmaceuticals Ltd
Inventors:
Nicholas Alan Zia, Paul Stephen Donnelly
Abstract: The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.
Type:
Grant
Filed:
April 11, 2019
Date of Patent:
April 9, 2024
Assignee:
Clarity Pharmaceuticals Ltd
Inventors:
Paul Stephen Donnelly, Nicholas Alan Zia
Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
Type:
Grant
Filed:
August 4, 2021
Date of Patent:
February 20, 2024
Assignee:
Clarity Pharmaceuticals Ltd.
Inventors:
Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
Abstract: Radiopharmaceutical compounds of general Formula (I) are based on a sarcophagine cage having a PEG linker-group X through to a group Y capable of binding to a biological receptor and an albumin-binding group Z for the treatment, diagnosis or imaging of diseases including cancer, and the production of such compounds and their complexes.
Type:
Application
Filed:
August 13, 2021
Publication date:
February 15, 2024
Applicant:
Clarity Pharmaceuticals Ltd
Inventors:
Lachlan Eion MCINNES, Paul Stephen DONNELLY, Ellen Marianne VAN DAM, Matthew John HARRIS
Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
Type:
Application
Filed:
August 11, 2023
Publication date:
November 30, 2023
Applicant:
Clarity Pharmaceuticals Ltd
Inventors:
Nicholas Alan ZIA, Paul Stephen DONNELLY
Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
Type:
Application
Filed:
June 7, 2022
Publication date:
October 6, 2022
Applicant:
Clarity Pharmaceuticals Ltd
Inventors:
Nicholas Alan ZIA, Paul Stephen DONNELLY
Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
Type:
Grant
Filed:
March 10, 2021
Date of Patent:
July 12, 2022
Assignee:
Clarity Pharmaceuticals Ltd
Inventors:
Nicholas Alan Zia, Paul Stephen Donnelly
Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
Type:
Application
Filed:
March 10, 2021
Publication date:
February 10, 2022
Applicant:
Clarity Pharmaceuticals Ltd
Inventors:
Nicholas Alan ZIA, Paul Stephen DONNELLY
Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
April 13, 2021
Assignee:
Clarity Pharmaceuticals Ltd
Inventors:
Nicholas Alan Zia, Paul Stephen Donnelly